The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Collaboration revenue - related party | 0 | - |
| Total operating expenses | 166,911 | - |
| Other income (expense), net | 14,835 | - |
| Net loss | -41,400 | -110,676 |
| Stock-based compensation | 8,652 | 20,860 |
| Depreciation and amortization | 3,097 | 6,205 |
| Net amortization/accretion on investment securities | 923 | 2,477 |
| Impairment of long-lived assets | 0 | 2,382 |
| Non-cash rent expense | 1,031 | 2,277 |
| Non-cash collaboration revenue - related party | 0 | 0 |
| Share of loss from equity method investments | 0 | 0 |
| Deposit placed in escrow | -12 | 2,711 |
| Prepaid expenses and other current assets | -1,010 | -1,242 |
| Other long-term assets | -315 | 1,503 |
| Accounts payable | -1,072 | -758 |
| Accrued and other current liabilities | 1,086 | -3,488 |
| Operating lease liabilities | -1,855 | -3,759 |
| Other long-term liabilities | 359 | 447 |
| Net cash used in operating activities | -29,688 | -91,959 |
| Purchases of property and equipment | 243 | 143 |
| Proceeds from sales of investments | 0 | - |
| Proceeds from maturities of investments | 61,912 | 110,300 |
| Purchase of investments | 49,734 | 60,146 |
| Net cash provided by investing activities | 11,935 | 50,011 |
| Proceeds from issuance of common stock from atm offering, net of commissions and issuance costs-ATMOffering | 2,979 | 11,516 |
| Proceeds from issuance of common stock from atm offering, net of commissions and issuance costs-Public Offering | 0 | 0 |
| Proceeds from cirm award (note 5) | 0 | 6,908 |
| Proceeds from issuance of common stock upon exercise of stock options | 0 | 0 |
| Proceeds from issuance of common stock under the employee stock purchase plan | 257 | 638 |
| Net cash provided by financing activities | 3,236 | 19,062 |
| Net change in cash and cash equivalents and restricted cash | -14,517 | -22,886 |
| Cash and cash equivalents at beginning of period | 85,510 | - |
| Cash and cash equivalents at end of period | 48,107 | - |
Allogene Therapeutics, Inc. (ALLO)
Allogene Therapeutics, Inc. (ALLO)